Ignyta Inc. (RXDX) Shares Gap Up to $6.30
Ignyta Inc. (NASDAQ:RXDX) gapped up before the market opened on Tuesday . The stock had previously closed at $6.26, but opened at $6.30. Ignyta shares last traded at $6.55, with a volume of 159,956 shares traded.
Several equities research analysts have commented on the company. Jefferies Group restated a “buy” rating and set a $20.00 price target on shares of Ignyta in a research note on Monday, June 6th. Cantor Fitzgerald reiterated a “buy” rating on shares of Ignyta in a research note on Wednesday, June 8th. Piper Jaffray Cos. lowered their target price on Ignyta from $32.00 to $20.00 and set an “overweight” rating for the company in a research note on Wednesday, August 10th. Credit Suisse Group AG reiterated a “buy” rating on shares of Ignyta in a research note on Tuesday, July 12th. Finally, Zacks Investment Research lowered Ignyta from a “hold” rating to a “sell” rating in a research note on Saturday, August 13th. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $16.36.
The company’s 50-day moving average price is $5.80 and its 200 day moving average price is $6.25. The firm’s market capitalization is $269.07 million.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/ignyta-inc-rxdx-shares-gap-up-to-6-30.html
Ignyta (NASDAQ:RXDX) last posted its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.70) EPS for the quarter, missing analysts’ consensus estimates of ($0.65) by $0.05. On average, analysts forecast that Ignyta Inc. will post ($2.83) EPS for the current fiscal year.
In other Ignyta news, Director James A. Bristol acquired 5,000 shares of the company’s stock in a transaction dated Monday, August 15th. The shares were acquired at an average cost of $5.65 per share, for a total transaction of $28,250.00. Following the completion of the purchase, the director now owns 21,667 shares of the company’s stock, valued at approximately $122,418.55. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 15.10% of the stock is owned by insiders.
Several institutional investors have recently bought and sold shares of the company. RS Investment Management Co. LLC raised its position in Ignyta by 20.0% in the second quarter. RS Investment Management Co. LLC now owns 2,032,793 shares of the biopharmaceutical company’s stock worth $11,018,000 after buying an additional 338,794 shares during the last quarter. Vanguard Group Inc. raised its position in Ignyta by 26.9% in the second quarter. Vanguard Group Inc. now owns 955,541 shares of the biopharmaceutical company’s stock worth $5,179,000 after buying an additional 202,330 shares during the last quarter. Lombard Odier Asset Management USA Corp raised its position in Ignyta by 15.3% in the second quarter. Lombard Odier Asset Management USA Corp now owns 811,016 shares of the biopharmaceutical company’s stock worth $4,396,000 after buying an additional 107,640 shares during the last quarter. BlackRock Fund Advisors raised its position in Ignyta by 38.5% in the second quarter. BlackRock Fund Advisors now owns 758,468 shares of the biopharmaceutical company’s stock worth $4,111,000 after buying an additional 210,745 shares during the last quarter. Finally, Artal Group S.A. raised its position in Ignyta by 50.0% in the second quarter. Artal Group S.A. now owns 750,000 shares of the biopharmaceutical company’s stock worth $4,065,000 after buying an additional 250,000 shares during the last quarter. Institutional investors and hedge funds own 62.39% of the company’s stock.
Ignyta, Inc is an oncology biotechnology company. The Company focuses on an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. Its Rx is focused on discovering, in licensing or acquiring, then developing and commercializing molecularly targeted therapies that, sequentially or in combination, are foundational for eradicating residual disease.
Receive News & Ratings for Ignyta Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ignyta Inc. and related companies with MarketBeat.com's FREE daily email newsletter.